PT3455216T - Derivados de piridinilo, composições farmacêuticas e suas utilizações como inibidores de aoc3 - Google Patents

Derivados de piridinilo, composições farmacêuticas e suas utilizações como inibidores de aoc3

Info

Publication number
PT3455216T
PT3455216T PT177217064T PT17721706T PT3455216T PT 3455216 T PT3455216 T PT 3455216T PT 177217064 T PT177217064 T PT 177217064T PT 17721706 T PT17721706 T PT 17721706T PT 3455216 T PT3455216 T PT 3455216T
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
pyridinyl derivatives
aoc3 inhibitors
aoc3
inhibitors
Prior art date
Application number
PT177217064T
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT3455216T publication Critical patent/PT3455216T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT177217064T 2016-05-12 2017-05-08 Derivados de piridinilo, composições farmacêuticas e suas utilizações como inibidores de aoc3 PT3455216T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16169356 2016-05-12

Publications (1)

Publication Number Publication Date
PT3455216T true PT3455216T (pt) 2021-01-18

Family

ID=55967162

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177217064T PT3455216T (pt) 2016-05-12 2017-05-08 Derivados de piridinilo, composições farmacêuticas e suas utilizações como inibidores de aoc3

Country Status (32)

Country Link
US (1) US9926292B2 (pt)
EP (1) EP3455216B1 (pt)
JP (1) JP6639702B2 (pt)
KR (1) KR20190003995A (pt)
CN (1) CN109153664B (pt)
AR (1) AR108462A1 (pt)
AU (1) AU2017262707B2 (pt)
CA (1) CA3023805A1 (pt)
CL (1) CL2018003158A1 (pt)
CO (1) CO2018012020A2 (pt)
CY (1) CY1123744T1 (pt)
DK (1) DK3455216T3 (pt)
EA (1) EA037188B1 (pt)
ES (1) ES2844926T3 (pt)
HR (1) HRP20202078T1 (pt)
HU (1) HUE053312T2 (pt)
IL (1) IL262662B (pt)
JO (1) JOP20170115B1 (pt)
LT (1) LT3455216T (pt)
MA (1) MA44965B1 (pt)
MX (1) MX2018013701A (pt)
PE (1) PE20190151A1 (pt)
PH (1) PH12018502376A1 (pt)
PL (1) PL3455216T3 (pt)
PT (1) PT3455216T (pt)
RS (1) RS61256B1 (pt)
SA (1) SA518400393B1 (pt)
SG (1) SG11201809687TA (pt)
SI (1) SI3455216T1 (pt)
TW (1) TWI746551B (pt)
UA (1) UA121930C2 (pt)
WO (1) WO2017194453A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019254371A1 (en) 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2020083264A1 (zh) * 2018-10-22 2020-04-30 广东东阳光药业有限公司 胍类衍生物及其用途
KR20210084537A (ko) * 2018-10-29 2021-07-07 베링거 인겔하임 인터내셔날 게엠베하 피리디닐 설폰아미드 유도체, 약제학적 조성물 및 이의 용도
WO2021083209A1 (en) 2019-10-29 2021-05-06 Eccogene (Shanghai) Co., Ltd. Ssao inhibitors and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518073A1 (de) * 1995-05-17 1996-11-21 Hoechst Ag Substituierte Benzyloxycarbonylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2536954C (en) * 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
CA2575411A1 (en) * 2004-07-27 2006-02-02 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
PL2479165T3 (pl) * 2009-09-16 2018-05-30 Astellas Pharma Inc. Związek glicynowy
ES2628850T3 (es) * 2011-03-15 2017-08-04 Astellas Pharma Inc. Compuesto de guanidina
JP6809464B2 (ja) 2015-08-06 2021-01-06 宇部興産株式会社 置換グアニジン誘導体

Also Published As

Publication number Publication date
PE20190151A1 (es) 2019-01-22
CO2018012020A2 (es) 2018-11-13
DK3455216T3 (da) 2021-01-18
JOP20170115B1 (ar) 2021-08-17
RS61256B1 (sr) 2021-01-29
AU2017262707B2 (en) 2020-11-19
EP3455216A1 (en) 2019-03-20
KR20190003995A (ko) 2019-01-10
US20170327483A1 (en) 2017-11-16
MX2018013701A (es) 2019-05-02
US9926292B2 (en) 2018-03-27
CA3023805A1 (en) 2017-11-16
JP6639702B2 (ja) 2020-02-05
CN109153664B (zh) 2021-07-16
PH12018502376B1 (en) 2019-04-08
SI3455216T1 (sl) 2021-02-26
UA121930C2 (uk) 2020-08-10
EA201892539A1 (ru) 2019-06-28
CL2018003158A1 (es) 2019-01-18
HRP20202078T1 (hr) 2021-02-19
NZ746586A (en) 2021-08-27
TWI746551B (zh) 2021-11-21
EA037188B1 (ru) 2021-02-17
IL262662B (en) 2021-07-29
AU2017262707A1 (en) 2018-10-11
CN109153664A (zh) 2019-01-04
MA44965B1 (fr) 2021-02-26
AR108462A1 (es) 2018-08-22
EP3455216B1 (en) 2020-11-04
SG11201809687TA (en) 2018-11-29
WO2017194453A1 (en) 2017-11-16
MA44965A (fr) 2019-03-20
TW201805278A (zh) 2018-02-16
IL262662A (en) 2018-12-31
ES2844926T3 (es) 2021-07-23
PH12018502376A1 (en) 2019-04-08
JP2019519495A (ja) 2019-07-11
CY1123744T1 (el) 2022-05-27
PL3455216T3 (pl) 2021-05-17
SA518400393B1 (ar) 2021-09-08
HUE053312T2 (hu) 2021-07-28
LT3455216T (lt) 2021-01-11

Similar Documents

Publication Publication Date Title
IL282584B (en) History of quinoline and pharmaceutical preparations containing them
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
IL248915A0 (en) Pyrrolidine-2,5-dione derivatives, preparations containing them and their use for the inhibition of ido1
IL258082B (en) History of benzaimidazole and pharmaceutical preparations containing them
IL247062A0 (en) Heterocyclic compounds, their preparation and pharmaceutical preparations containing them
EP3214090A4 (en) Thionucleoside derivative or salt thereof, and pharmaceutical composition
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
IL250422A0 (en) History of pyrrolidinone, and pharmaceutical preparations containing them
HK1256674A1 (zh) 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途
IL262662B (en) History of pyridinyl, pharmaceutical preparations and their uses as aoc3 inhibitors
EP3124486A4 (en) Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
IL249308B (en) The history of quinoline, their preparation and pharmaceutical preparations containing them
IL248785B (en) Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents
IL258160B (en) Biaryl derivatives, pharmaceutical preparations containing them and their uses
IL248773B (en) History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them
IL304109A (en) Pharmaceutical preparations containing spinamide
IL258977B (en) Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them
IL247220A0 (en) Amino pyrazoline derivatives, preparations containing them and their uses
IL254711B (en) History of diazepine-indole and medicinal preparations containing them
IL259900A (en) Aminoazole derivatives, compositions containing same and uses thereof
SI3558261T1 (sl) Farmacevtski sestavki, ki obsegajo safinamid
ZA201607127B (en) Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
EP3326631A4 (en) PAC-1 COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME